Compare Solaredge Technologies Inc (SEDG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Solaredge Technologies Inc trades at $32.23 (market cap $2.05B), while State Street SPDR S&P Biotech ETF trades at $159.46. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| SEDG | XBI | |
|---|---|---|
Market Cap | $2.05B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $78.51 | $164.28 |
52-Week Low | $25.10 | $86.92 |
Enterprise Value | $1.91B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.04, down 0.53% on the day, reflecting ongoing volatility amid mixed financial performance. The stock exhibits a bearish technical trend, with negative profitability metrics including a net income margin of -20.29% and ROE of -58.42% for 2026. Recent Q2 2026 earnings beat expectations with EPS of $0.06, but weak Q3 revenue guidance has pressured shares. Cash flow improved in 2025 with net cash flow of $138.60 million, though debt levels remain elevated.
The outlook is cautious due to persistent losses, high dependence on policy incentives, and a challenging U.S. residential solar market. Analyst consensus is mixed with a hold-heavy rating (58.34%) and a $35.15 price target, suggesting limited near-term upside. Key risks include execution missteps, competitive pressures, and macroeconomic headwinds, requiring careful monitoring of margin recovery and demand trends.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
